Why Invest

Avivagen offers scientifically-proven, nature-derived products that are helping livestock and pets. Our OxC-beta Livestock product is supporting productivity through enhanced feed flavor. Vivamune and Dr. Tobias All-in-One Dog chews support overall health and quality of life in dogs.

Fast facts for investors

Five families of patents that extend for years
VIV is listed on both the TSXV and the OTCQB
Analyst coverage by U.S. based Zachs Small-Cap research and Noble Capital Markets, with more to come
Attractive business model with fully integrated, recurring, increasing revenue profile
Record contract in Mexico already secured
New sales now in South East Asia

Avivagen on the Capital Markets

VIV on TSXV

VIVXF on OTCQB

Shares outstanding:

56.8M

Market capitalization:

$24.9M

Recent price:

$0.44 per share

Read our Financial Updates

Corporate Filings

Financial Reports

Please note that Avivagen’s fiscal year ends October 31st. For additional financial and corporate documents, please visit SEDAR here.

Healthy Food thanks to healthy livestock

OxC-beta is easy-to-use because it comes as powder and is very affordable.

OxC-beta™ For Livestock – $1.2 Billion Tonne Annual Worldwide Market

Worldwide Purchase Orders

Better pet health

Sales are growing since more and more people are seeing the difference our product has on their pets. Dogs are living their best life, especially those in their older years. In North America, sales are on Amazon and JV with Mimi’s Rock (TSXV:MIMI).

OxC-beta™ For Pets – $635 Million Worldwide Market
Read our Corporate Filings
Read our latest Investor Update
See our Financial Reports
Please note that Avivagen’s fiscal year ends October 31st. For additional financial and corporate documents, please visit SEDAR here.

Analysts

Avivagen is followed by the analysts listed below. Please note that any opinions, estimates or forecasts regarding Avivagen performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Avivagen or its management. By reference to the information below, Avivagen does not imply its endorsement of or concurrence with any information, conclusions or recommendations as a result of analyst coverage.

Doug Cooper, Beacon Securities Limited – (416) 643-3863

David Bautz, Zack’s Small Cap Research – (312) 265-9474

Joe Gomes, Noble Capital Markets – (561) 998-5487

Partners

Avivagen is developing and commercializing products
that promote health in animals and humans.

Avivagen offers its commercial partners scientifically backed, evidence-based products that are in high demand from multiple channels including veterinarians, farmers and producers, pet owners and retailers.
Avivagen maintains the highest manufacturing standards and is a proud member of the NASC, a self-regulating body, which protects and enhances the integrity of the animal health product industry.
Avivagen is actively collaborating with companies in Canada, the United States, Mexico, South Korea, Vietnam, Taiwan, Brazil, and Thailand, and we are seeking more relationships internationally.